Oscar Health Inc. (OSCR)$22.64
Market Cap: 3.31 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Oscar Health Inc. (OSCR).
HEALTHCARE
HEALTHCARE PLANS
DCF ready
Valuation
0.5x
EV/FCF, 198.0% FCF yield
Quality
-45.3%
ROIC, 3701.9% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 0.9x current ratio
Superinvestors
0
No tracked positions
Strengths to research
- Free cash flow compounded at 38.4% over five years.
- Free cash flow margin is healthy at 3701.9%.
- Debt/equity looks manageable at 0.0x.
Watchouts
- Current ratio is below 1 at 0.9x.
Annual data: 7 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for OSCR.
Grade D
40
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| OSCR Target | Oscar Health Inc. | $3.3B | -13.4x | 0.5x | -45.3% | N/A | 3701.9% | N/A | N/A | N/A |
| NVST | Envista Holdings Corp. | $2.9B | 83.7x | 13.5x | 1.0% | 7.1% | 8.5% | 54.7% | 0.7x | N/A |
| BLCO | Bausch + Lomb Corp | $4.0B | -15.6x | -131.6x | -3.1% | 8.4% | -1.3% | N/A | 16.9x | N/A |
| ITGR | Integer Holdings Corp. | $4.1B | 30.9x | 49.8x | 3.5% | 11.5% | 5.7% | 27.0% | 3.3x | N/A |
| IMVT | Immunovant Inc. | $2.6B | -12.3x | -4.1x | -59.3% | N/A | N/A | N/A | N/A | N/A |
| PCVX | Vaxcyte Inc. | $4.4B | -8.4x | -6.3x | -0.0% | N/A | N/A | N/A | N/A | N/A |
| OGN | Organon & Co. | $2.3B | 18.7x | 19.2x | 2.0% | -1.0% | 8.7% | 53.3% | N/A | N/A |
| NAMS | Newamsterdam Pharma Co Nv | $2.2B | -20.6x | -11.7x | -29.7% | N/A | -657.8% | N/A | N/A | N/A |
| ACHC | Acadia Healthcare Co. | $2.1B | -1.9x | -10.2x | -24.8% | 9.7% | -13.3% | N/A | N/A | N/A |
Financial Charts
No financial data available for OSCR (annual).